Drug Profile
ALX 0651
Alternative Names: ALX-0651Latest Information Update: 22 Jun 2018
Price :
$50
*
At a glance
- Originator Ablynx
- Class Antineoplastics
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 06 Mar 2012 Discontinued - Phase-I for Cancer in Europe (IV)
- 29 Jun 2011 Phase-I clinical trials in Cancer in Europe (IV)